Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 586

1.

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID:
15654790
2.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.

Am J Gastroenterol. 2004 Nov;99(11):2195-203.

PMID:
15555002
3.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
4.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
5.

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.

PMID:
15290660
6.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team.

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
7.
8.

Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.

9.

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D; Lotronex Investigator Team.

Am J Gastroenterol. 2002 Dec;97(12):3139-46.

PMID:
12492201
10.

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.

Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D.

Aliment Pharmacol Ther. 2008 Jul;28(2):239-49. doi: 10.1111/j.1365-2036.2008.03730.x. Epub 2008 May 7.

11.

Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.

Chang FY, Lu CL, Chen CY, Luo JC.

J Gastroenterol Hepatol. 2007 Dec;22(12):2266-72. Epub 2007 Jun 7.

PMID:
17559369
12.

Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.

Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, Magni E, Porro GB.

Eur Rev Med Pharmacol Sci. 2010 Mar;14(3):155-62.

PMID:
20391952
13.

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.

Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG.

Aliment Pharmacol Ther. 1999 Nov;13(11):1419-27.

14.

A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.

Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW.

Aliment Pharmacol Ther. 2001 Apr;15(4):525-37.

15.

Pharmacology and clinical experience with alosetron.

Camilleri M.

Expert Opin Investig Drugs. 2000 Jan;9(1):147-59. Review.

PMID:
11060667
16.

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.

Lewis JH.

Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. doi: 10.1586/egh.09.72.

PMID:
20136586
17.

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.

Am J Gastroenterol. 2001 Mar;96(3):803-11.

PMID:
11280555
18.

Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.

Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG.

Am J Gastroenterol. 2008 Oct;103(10):2562-9. doi: 10.1111/j.1572-0241.2008.02115.x. Epub 2008 Sep 4.

PMID:
18775020
19.

Efficacy of linaclotide for patients with chronic constipation.

Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM.

Gastroenterology. 2010 Mar;138(3):886-95.e1. doi: 10.1053/j.gastro.2009.12.050. Epub 2010 Jan 4.

PMID:
20045700
20.

Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.

Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW.

Aliment Pharmacol Ther. 2008 Jan 15;27(2):197-206. Epub 2007 Oct 31.

Supplemental Content

Support Center